CNC
Get informed when a big investor buys or sells
+ FollowApril 28, 2026 - AI Summary
Undervalued by 50.4% based on the discounted cash flow analysis.
| Market cap | $30.13 Billion |
|---|---|
| Enterprise Value | $26.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-13.61 |
| Beta | 1.09 |
| Outstanding Shares | 492,069,000 |
| P/E Ratio | -4.65 |
|---|---|
| PEG | -26.51 |
| Price to Sales | 0.16 |
| Price to Book Ratio | 1.47 |
| Enterprise Value to Revenue | 0.13 |
| Enterprise Value to EBIT | -4.07 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.66 |
| Debt to Equity | 0.81 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8660▲ 18.27% |
|---|---|
| Total Calls | 11,188,200▼ 38.21% |
| Total Puts | 9,689,500▼ 21.69% |
Holdings and activity of institutional investors.
| Ownership % | 96.43%▼ 0.58% |
|---|---|
| Total Invested | $15.50B▼ 21.08% |
| Investors Holding | 910▼ 62.00% |
No data
Controls taxation, trade, and entitlement spending (Medicare, Medicaid). This committee is paramount, as it directly shapes the funding, regulatory framework, and tax environment for Centene's primary business lines.
Allocates discretionary federal spending. Its subcommittees determine precise funding for healthcare programs (Medicaid, Medicare), directly impacting Centene's revenues from government contracts.
Directly regulates health policy, drug approvals (FDA), and labor laws. This committee's decisions profoundly impact Centene's operational costs (labor), drug formularies, and overall healthcare market dynamics.
Drafts the budget resolution, directly influencing overall federal spending levels, including critical funding for Medicare and Medicaid programs that Centene heavily relies on for revenue.